Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedDec 03, 2025
DataAggregated Company Financials
Companies153
  • 7D-0.6%
  • 3M-3.9%
  • 1Y-4.9%
  • YTD-5.8%

The Healthcare is pretty flat in the last 7 days, but Elekta has stood out, gaining 25%. As for the longer term, the industry has declined 4.9% in the last year. As for the next few years, earnings are expected to grow by 30% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 03 Dec 2025SEK 594.1bSEK 230.8bSEK 3.6b42.2x165.6x2.6x
Fri, 31 Oct 2025SEK 613.1bSEK 228.2bSEK 3.3b46.5x184.6x2.7x
Sun, 28 Sep 2025SEK 593.6bSEK 227.1bSEK 6.6b43.5x89.8x2.6x
Tue, 26 Aug 2025SEK 628.8bSEK 227.2bSEK 6.3b48.3x100x2.8x
Thu, 24 Jul 2025SEK 626.2bSEK 225.5bSEK 6.4b45.9x97.6x2.8x
Sat, 21 Jun 2025SEK 593.9bSEK 226.9bSEK 5.9b45x101.4x2.6x
Mon, 19 May 2025SEK 610.2bSEK 224.9bSEK 5.6b36.5x108.9x2.7x
Wed, 16 Apr 2025SEK 551.7bSEK 221.9bSEK 5.3b33x104.9x2.5x
Fri, 14 Mar 2025SEK 542.9bSEK 206.3bSEK 4.7b36.1x115.7x2.6x
Sun, 09 Feb 2025SEK 600.9bSEK 220.4bSEK 2.5b42x238.4x2.7x
Tue, 07 Jan 2025SEK 588.1bSEK 202.6b-SEK 2,502,690,753.8640.4x-235x2.9x
Thu, 05 Dec 2024SEK 516.5bSEK 199.3b-SEK 2,879,163,500.0137.9x-179.4x2.6x
Sat, 02 Nov 2024SEK 524.9bSEK 200.0b-SEK 2,886,644,216.9836.7x-181.8x2.6x
Mon, 30 Sep 2024SEK 620.5bSEK 199.9b-SEK 2,815,696,552.4540.2x-220.4x3.1x
Wed, 28 Aug 2024SEK 603.5bSEK 199.9b-SEK 2,341,926,427.3739.3x-257.7x3x
Fri, 26 Jul 2024SEK 598.9bSEK 199.0b-SEK 2,856,203,905.9141.8x-209.7x3x
Sun, 23 Jun 2024SEK 557.3bSEK 195.5b-SEK 3,182,934,253.1735.3x-175.1x2.9x
Tue, 21 May 2024SEK 552.5bSEK 196.2b-SEK 2,920,427,970.2037.4x-189.2x2.8x
Thu, 18 Apr 2024SEK 516.4bSEK 193.1b-SEK 3,172,396,485.6844.5x-162.8x2.7x
Sat, 16 Mar 2024SEK 521.6bSEK 192.3b-SEK 3,668,382,588.5343.5x-142.2x2.7x
Mon, 12 Feb 2024SEK 509.6bSEK 191.4b-SEK 4,204,413,743.1548.9x-121.2x2.7x
Wed, 10 Jan 2024SEK 549.1bSEK 191.3b-SEK 965,498,035.0048.3x-568.8x2.9x
Fri, 08 Dec 2023SEK 507.1bSEK 190.3b-SEK 1,098,047,905.0050.3x-461.8x2.7x
Sun, 05 Nov 2023SEK 458.1bSEK 190.0b-SEK 1,067,305,617.0040.3x-429.2x2.4x
Tue, 03 Oct 2023SEK 450.7bSEK 185.0b-SEK 2,028,250,505.0036.3x-222.2x2.4x
Thu, 31 Aug 2023SEK 461.7bSEK 185.7b-SEK 1,770,203,896.0037.5x-260.8x2.5x
Sat, 29 Jul 2023SEK 478.8bSEK 183.7b-SEK 1,025,280,705.0040.3x-467x2.6x
Mon, 26 Jun 2023SEK 483.3bSEK 179.1b-SEK 798,027,738.0043.6x-605.6x2.7x
Wed, 24 May 2023SEK 520.4bSEK 177.5b-SEK 841,964,752.0043.5x-618.1x2.9x
Fri, 21 Apr 2023SEK 507.3bSEK 173.0b-SEK 1,518,275,789.0035x-334.1x2.9x
Sun, 19 Mar 2023SEK 482.8bSEK 172.3b-SEK 1,416,844,503.0035.9x-340.7x2.8x
Tue, 14 Feb 2023SEK 512.1bSEK 169.4bSEK 445.8m35.8x1148.8x3x
Thu, 12 Jan 2023SEK 493.0bSEK 165.9bSEK 698.5m32.7x705.9x3x
Sat, 10 Dec 2022SEK 491.1bSEK 165.1bSEK 800.5m32.1x613.5x3x
Price to Earnings Ratio

613.5x


Total Market Cap: SEK 491.1bTotal Earnings: SEK 800.5mTotal Revenue: SEK 165.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -121.1x202320242025
Current Industry PE
  • Investors are optimistic on the Swedish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 166x which is higher than its 3-year average PE of -121x.
  • The industry is trading close to its 3-year average PS ratio of 2.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 65% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market0.56%
Healthcare-0.58%
Biotech0.062%
Healthcare Services-0.05%
Medical Equipment-0.13%
Life Sciences-0.70%
Pharma-1.79%
Healthtech-3.31%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 127x.
    • Analysts are expecting annual earnings growth of 19.6%, which is lower than the prior year's growth of 28.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 39% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 20% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
EKTA B ElektaSEK 55.6524.9%
+SEK 4.2b		-9.5%PE72.8x
BIOA B BioArcticSEK 304.004.5%
+SEK 1.2b		67.1%PE26.9x
MCOV B MedicoverSEK 233.001.7%
+SEK 604.2m		28.7%PE47.7x
SANION SanionaSEK 18.0014.2%
+SEK 309.2m		143.9%PE4.3x
HNSA Hansa BiopharmaSEK 32.349.4%
+SEK 282.9m		2.5%PS18.4x

Latest News

SUS
SEK 33.10
Surgical Science Sweden
7D
-55.9%
1Y
-77.4%
EKTA B
SEK 55.65
Elekta
7D
24.9%
1Y
-9.5%

EKTA B: Future Outlook Shows Balanced Risks With Expected China Sales Recovery

Analysts have increased their price target for Elekta from $53.79 to $56.77. This adjustment is based on improved forecasts for revenue growth and profit margin, along with a slightly higher estimated fair value.
SOBI
SEK 337.80
Swedish Orphan Biovitrum
7D
-0.4%
1Y
11.0%

Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S

Dec 01
Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S
MCOV B
SEK 233.00
Medicover
7D
1.7%
1Y
28.7%

What Does Medicover AB (publ)'s (STO:MCOV B) Share Price Indicate?

Nov 30
What Does Medicover AB (publ)'s (STO:MCOV B) Share Price Indicate?
CANTA
SEK 4.21
Cantargia
7D
22.7%
1Y
128.9%
CRNO B
SEK 7.81
Cereno Scientific
7D
11.6%
1Y
28.0%
SANION
SEK 18.00
Saniona
7D
14.2%
1Y
143.9%
VITR
SEK 144.70
Vitrolife
7D
-3.5%
1Y
-34.8%

VITR: Current Metrics And Stable Margins Will Support Further Upside

Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.
SECT B
SEK 277.00
Sectra
7D
-4.0%
1Y
-3.8%
BONEX
SEK 186.50
Bonesupport Holding
7D
-4.3%
1Y
-48.3%

BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes

Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.
ASKER
SEK 90.15
Asker Healthcare Group
7D
-2.8%
1Y
n/a

We Think Asker Healthcare Group (STO:ASKER) Can Stay On Top Of Its Debt

Nov 25
We Think Asker Healthcare Group (STO:ASKER) Can Stay On Top Of Its Debt
VIMIAN
SEK 28.80
Vimian Group
7D
-7.0%
1Y
-35.4%

VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience

Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.
CAMX
SEK 598.50
Camurus
7D
-1.8%
1Y
7.1%

CAMX: New European Launch And Regulatory Progress Will Drive Future Upside

Camurus's analyst price target has been slightly revised downward from SEK 801.17 to SEK 800.86. This change reflects updated assessments on growth and profitability expectations according to analysts.
BIOA B
SEK 304.00
BioArctic
7D
4.5%
1Y
67.1%
HNSA
SEK 32.34
Hansa Biopharma
7D
9.4%
1Y
2.5%

Hansa Biopharma AB (publ) (STO:HNSA) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Nov 16
Hansa Biopharma AB (publ) (STO:HNSA) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
GETI B
SEK 211.80
Getinge
7D
0.3%
1Y
25.9%